Overview

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases

Status:
Not yet recruiting

Trial end date:
2025-03-22

Target enrollment:

Participant gender:

Summary

A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Bevacizumab